Mike Ross

Managing Partner

Mike Ross’ career spans over 15 years in venture capital, which followed 21 years in senior operating executive roles for leading biotechnology companies.

He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002.

Prior experience
Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). He was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Mike served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova.

Academic credentials
AB, Dartmouth College; PhD, Chemistry, Caltech; Post-Doctoral Fellowship. Molecular Biology, Harvard.

Outside of SV
Mike serves on the Board of the Thayer School of Engineering (Dartmouth College). Mike enjoys tennis, photography and hiking.

Team
Investment Team

Sector
Biotechnology

Assistant
Maura Williams

Office
Boston

Current Portfolio

Past Portfolio

Aderis Pharmaceuticals, Inc.
Avera Pharmaceuticals, Inc.
GlycoFi, Inc.
Ikano Therapeutics, Inc. (fka Intranasal)
Itero Holdings, LLC
Link Medicine, LLC
Mpex Pharmaceuticals, Inc.
NeurogesX, Inc.
Rempex Pharmaceuticals, Inc.
Rinat Neurosciences Corp.
Sapphire Therapeutics, Inc. (fka: Rejuvenon)